All In MedTech

Device Trial Radar · NCT05701098

SOUND Pivotal Trial - (Sonomotion stOne comminUtion resoNance ultrasounD)

Pivotal Study of the SonoMotion Break Wave™ (Trade Mark) System for the Comminution of Urinary Tract Stones

Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

64

Actual

Start

Oct 9, 2023

Primary completion

Jun 18, 2025

Study completion Jul 31, 2025

Sponsor

Lead sponsor
SonoMotionNot on our public-company list
Sponsor type
Industry
First posted
Jan 27, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to test the Break Wave™ system in patients with upper urinary tract stones. The main question it aims to answer is whether the device is safe and effective in fragmenting (breaking) stones. Participants will a) undergo the Break Wave™ procedure, b) have a telehealth visit at 2 weeks, and c) return for an imaging study at approximately 10 weeks post-procedure.

Conditions

  • Kidney Stone
  • Urolithiasis
  • Nephrolithiasis
  • Renal Calculi
  • Kidney Calculi
  • Nephrolith
  • Urinary Calculi

Interventions

  • Break Wave extracorporeal lithotripsyDevice

    The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an ultrasound imaging system and a therapy probe driven by a high voltage generator. The probe will be placed on the patient's skin, the stone located via diagnostic ultrasound and up to 30 minutes of therapy will be delivered to the stone. The therapy probe accommodates coaxial alignment of an ultrasound imaging probe for treatment guidance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Effectiveness EndpointTime frame: 10 +/- 2 weeks post final Break Wave procedure
  2. Primary Safety EndpointTime frame: During procedure and through 90 days post-procedure

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California- San Diego

    San Diego, California

  • University of California - San Francisco

    San Francisco, California

  • Kaiser Permanente

    Santa Clara, California

7 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.